| Jeffrey Scott Walsh, | |
|
542 E 1600 S, Bountiful, UT 84010-4016 | |
| (801) 979-4077 | |
| Not Available |
| Full Name | Jeffrey Scott Walsh |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Primary Care |
| Location | 542 E 1600 S, Bountiful, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962070102 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WG0000X | Registered Nurse - General Practice | 10676959-3102 (Utah) | Secondary |
| 363LP2300X | Nurse Practitioner - Primary Care | 10676959-4405 (Utah) | Primary |
| Entity Name | Tanner Memorial Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447239355 PECOS PAC ID: 4284547985 Enrollment ID: O20031110000132 |
News Archive
Internet-based company Show Your Logo joined forces with its clientele in October to support the fight against breast cancer with a fundraiser for Susan G. Komen for the Cure®, the world's largest network of breast cancer survivors and activists.
Researchers scour what is known to come up with a hypothesis of why blood clots can be a major problem in COVID-19
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
The Society of NeuroInterventional Surgery and M2S, a leading clinical registry provider, are pleased to announce the launch of the new Cerebral Aneurysm module for the NeuroVascular Quality Initiative (NVQI®), and the planned launch for the Cerebral Arteriovenous Malformations (AVMs) module in early October.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Scott Walsh, 542 E 1600 S, Bountiful, UT 84010-4016 Ph: (801) 979-4077 | Jeffrey Scott Walsh, 542 E 1600 S, Bountiful, UT 84010-4016 Ph: (801) 979-4077 |
News Archive
Internet-based company Show Your Logo joined forces with its clientele in October to support the fight against breast cancer with a fundraiser for Susan G. Komen for the Cure®, the world's largest network of breast cancer survivors and activists.
Researchers scour what is known to come up with a hypothesis of why blood clots can be a major problem in COVID-19
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
The Society of NeuroInterventional Surgery and M2S, a leading clinical registry provider, are pleased to announce the launch of the new Cerebral Aneurysm module for the NeuroVascular Quality Initiative (NVQI®), and the planned launch for the Cerebral Arteriovenous Malformations (AVMs) module in early October.
› Verified 2 days ago
Kenzlee Wooden, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 845 S Main St Ste A7, Bountiful, UT 84010 Phone: 801-298-0903 | |
Daelyn Tasha Clawson, RN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 390 N Main St, Bountiful, UT 84010 Phone: 801-397-6670 | |
Miss Lauren Lightfield, AGACNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 458 N 500 W, Bountiful, UT 84010 Phone: 801-292-9355 Fax: 801-296-8050 | |
Niari Anne Mcfarland, NURSE PRACTITIONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 523 N Main, Bountiful, UT 84010 Phone: 801-951-2273 | |
Sarah Elizabeth Mcmillin, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 111 W 3100 S, Bountiful, UT 84010 Phone: 801-668-7479 | |
Mistie Sue Manning, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1551 Renaissance Towne Dr Ste 370, Bountiful, UT 84010 Phone: 801-747-7244 | |
Dr. Rachel Starr Wagner Pollard, DNP, APRN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 320 W 500 S Ste 210, Bountiful, UT 84010 Phone: 801-797-9121 |